Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + R2-ICE in R/R DLBCL or HGBL
NCT05050630Phase 2Unknown
- Sponsor
- Academy of Military Medical Sciences
- Start
- Aug 2021
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), sponsored by Academy of Military Medical Sciences. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)high grade B-cell lymphoma (HGBCL)
Beyond the preview
Go deeper on NCT05050630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05050630.